Effect of triptorelin on lower urinary tract symptoms in Australian prostate cancer patients

Henry H Woo, Declan G. Murphy, Gerard M. Testa, Jeremy P. Grummet, Michael Chong, Andrew P. Stork

Research output: Contribution to journalArticleResearchpeer-review

2 Citations (Scopus)

Abstract

Purpose: Prostate cancer is often comorbidly associated with lower urinary tract symptoms (LUTS), but few studies have assessed the effects of androgen deprivation therapy on LUTS in this patient group. Patients and methods: We conducted a prospective, noninterventional, multicenter, observational study to assess the effectiveness of triptorelin (11.25 mg every 12 weeks) over 48 weeks in men presenting with local stage T3/4 prostate cancer and moderate to severe LUTS (International Prostate Symptom Score [IPSS] >7) in a routine practice setting in Australia. Results: Of the 44 men who enrolled, effectiveness data were available for 39 men. By the end of the study, 30% of men no longer met the IPSS criteria for moderate to severe LUTS. The proportion of patients with moderate to severe LUTS was 69.6% (16/23) at week 48 and 76.9% (30/39) at the last available visit (coprimary outcomes). An IPSS reduction of ≥3 from week 0 was observed in 47% of men at week 4, 56% at week 24, 61% (14/23) at week 48, and 61.5% (24/39) at the last available visit. Quality of life was rated as mostly satisfied-to-delighted by 39.5% of patients at week 0, 53.9% at week 24, and 77.3% at week 48. Triptorelin was well tolerated with 8 treatment-related adverse events reported, half of which were hot flushes; 5 patients discontinued due to the reported treatment-related adverse events. Conclusion: This observational study suggests that triptorelin improves moderate to severe LUTS in prostate cancer patients in a routine clinical practice setting.

Original languageEnglish
Pages (from-to)27-35
Number of pages9
JournalResearch and Reports in Urology
Volume9
DOIs
Publication statusPublished - 23 Feb 2017
Externally publishedYes

Keywords

  • GnRH agonist
  • IPSS

Cite this

Woo, Henry H ; Murphy, Declan G. ; Testa, Gerard M. ; Grummet, Jeremy P. ; Chong, Michael ; Stork, Andrew P. / Effect of triptorelin on lower urinary tract symptoms in Australian prostate cancer patients. In: Research and Reports in Urology. 2017 ; Vol. 9. pp. 27-35.
@article{202408b5db80469fb506872af4b6cd84,
title = "Effect of triptorelin on lower urinary tract symptoms in Australian prostate cancer patients",
abstract = "Purpose: Prostate cancer is often comorbidly associated with lower urinary tract symptoms (LUTS), but few studies have assessed the effects of androgen deprivation therapy on LUTS in this patient group. Patients and methods: We conducted a prospective, noninterventional, multicenter, observational study to assess the effectiveness of triptorelin (11.25 mg every 12 weeks) over 48 weeks in men presenting with local stage T3/4 prostate cancer and moderate to severe LUTS (International Prostate Symptom Score [IPSS] >7) in a routine practice setting in Australia. Results: Of the 44 men who enrolled, effectiveness data were available for 39 men. By the end of the study, 30{\%} of men no longer met the IPSS criteria for moderate to severe LUTS. The proportion of patients with moderate to severe LUTS was 69.6{\%} (16/23) at week 48 and 76.9{\%} (30/39) at the last available visit (coprimary outcomes). An IPSS reduction of ≥3 from week 0 was observed in 47{\%} of men at week 4, 56{\%} at week 24, 61{\%} (14/23) at week 48, and 61.5{\%} (24/39) at the last available visit. Quality of life was rated as mostly satisfied-to-delighted by 39.5{\%} of patients at week 0, 53.9{\%} at week 24, and 77.3{\%} at week 48. Triptorelin was well tolerated with 8 treatment-related adverse events reported, half of which were hot flushes; 5 patients discontinued due to the reported treatment-related adverse events. Conclusion: This observational study suggests that triptorelin improves moderate to severe LUTS in prostate cancer patients in a routine clinical practice setting.",
keywords = "GnRH agonist, IPSS",
author = "Woo, {Henry H} and Murphy, {Declan G.} and Testa, {Gerard M.} and Grummet, {Jeremy P.} and Michael Chong and Stork, {Andrew P.}",
year = "2017",
month = "2",
day = "23",
doi = "10.2147/RRU.S125791",
language = "English",
volume = "9",
pages = "27--35",
journal = "Research and Reports in Urology",
issn = "2253-2447",
publisher = "Dove Medical Press Ltd.",

}

Effect of triptorelin on lower urinary tract symptoms in Australian prostate cancer patients. / Woo, Henry H; Murphy, Declan G.; Testa, Gerard M.; Grummet, Jeremy P.; Chong, Michael; Stork, Andrew P.

In: Research and Reports in Urology, Vol. 9, 23.02.2017, p. 27-35.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Effect of triptorelin on lower urinary tract symptoms in Australian prostate cancer patients

AU - Woo, Henry H

AU - Murphy, Declan G.

AU - Testa, Gerard M.

AU - Grummet, Jeremy P.

AU - Chong, Michael

AU - Stork, Andrew P.

PY - 2017/2/23

Y1 - 2017/2/23

N2 - Purpose: Prostate cancer is often comorbidly associated with lower urinary tract symptoms (LUTS), but few studies have assessed the effects of androgen deprivation therapy on LUTS in this patient group. Patients and methods: We conducted a prospective, noninterventional, multicenter, observational study to assess the effectiveness of triptorelin (11.25 mg every 12 weeks) over 48 weeks in men presenting with local stage T3/4 prostate cancer and moderate to severe LUTS (International Prostate Symptom Score [IPSS] >7) in a routine practice setting in Australia. Results: Of the 44 men who enrolled, effectiveness data were available for 39 men. By the end of the study, 30% of men no longer met the IPSS criteria for moderate to severe LUTS. The proportion of patients with moderate to severe LUTS was 69.6% (16/23) at week 48 and 76.9% (30/39) at the last available visit (coprimary outcomes). An IPSS reduction of ≥3 from week 0 was observed in 47% of men at week 4, 56% at week 24, 61% (14/23) at week 48, and 61.5% (24/39) at the last available visit. Quality of life was rated as mostly satisfied-to-delighted by 39.5% of patients at week 0, 53.9% at week 24, and 77.3% at week 48. Triptorelin was well tolerated with 8 treatment-related adverse events reported, half of which were hot flushes; 5 patients discontinued due to the reported treatment-related adverse events. Conclusion: This observational study suggests that triptorelin improves moderate to severe LUTS in prostate cancer patients in a routine clinical practice setting.

AB - Purpose: Prostate cancer is often comorbidly associated with lower urinary tract symptoms (LUTS), but few studies have assessed the effects of androgen deprivation therapy on LUTS in this patient group. Patients and methods: We conducted a prospective, noninterventional, multicenter, observational study to assess the effectiveness of triptorelin (11.25 mg every 12 weeks) over 48 weeks in men presenting with local stage T3/4 prostate cancer and moderate to severe LUTS (International Prostate Symptom Score [IPSS] >7) in a routine practice setting in Australia. Results: Of the 44 men who enrolled, effectiveness data were available for 39 men. By the end of the study, 30% of men no longer met the IPSS criteria for moderate to severe LUTS. The proportion of patients with moderate to severe LUTS was 69.6% (16/23) at week 48 and 76.9% (30/39) at the last available visit (coprimary outcomes). An IPSS reduction of ≥3 from week 0 was observed in 47% of men at week 4, 56% at week 24, 61% (14/23) at week 48, and 61.5% (24/39) at the last available visit. Quality of life was rated as mostly satisfied-to-delighted by 39.5% of patients at week 0, 53.9% at week 24, and 77.3% at week 48. Triptorelin was well tolerated with 8 treatment-related adverse events reported, half of which were hot flushes; 5 patients discontinued due to the reported treatment-related adverse events. Conclusion: This observational study suggests that triptorelin improves moderate to severe LUTS in prostate cancer patients in a routine clinical practice setting.

KW - GnRH agonist

KW - IPSS

UR - http://www.scopus.com/inward/record.url?scp=85020934144&partnerID=8YFLogxK

U2 - 10.2147/RRU.S125791

DO - 10.2147/RRU.S125791

M3 - Article

VL - 9

SP - 27

EP - 35

JO - Research and Reports in Urology

JF - Research and Reports in Urology

SN - 2253-2447

ER -